Clinical Trial Update: A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZT [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating two doses of ddC in children with symptomatic HIV infection intolerant to AZT or with disease progression on AZT.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• 2',3'-Dideoxycytidine (ddC) (ddC)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED